870 related articles for article (PubMed ID: 32918855)
21. Review of studies of severe acute respiratory syndrome related coronavirus-2 pathogenesis in human organoid models.
Egilmezer E; Rawlinson WD
Rev Med Virol; 2021 Nov; 31(6):e2227. PubMed ID: 33763936
[TBL] [Abstract][Full Text] [Related]
22. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.
Ning Q; Wu D; Wang X; Xi D; Chen T; Chen G; Wang H; Lu H; Wang M; Zhu L; Hu J; Liu T; Ma K; Han M; Luo X
Signal Transduct Target Ther; 2022 Feb; 7(1):57. PubMed ID: 35197452
[TBL] [Abstract][Full Text] [Related]
23. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
Mishra J; Prasun C; Sahoo PK; Nair MS
Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
[TBL] [Abstract][Full Text] [Related]
24. A double edged-sword - The Complement System during SARS-CoV-2 infection.
Santiesteban-Lores LE; Amamura TA; da Silva TF; Midon LM; Carneiro MC; Isaac L; Bavia L
Life Sci; 2021 May; 272():119245. PubMed ID: 33609539
[TBL] [Abstract][Full Text] [Related]
25. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
Goel B; Bhardwaj N; Tripathi N; Jain SK
Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
[TBL] [Abstract][Full Text] [Related]
26. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
27. Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm.
Pum A; Ennemoser M; Adage T; Kungl AJ
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33445810
[TBL] [Abstract][Full Text] [Related]
28. A Cytokine Circus with a Viral Ringleader: SARS-CoV-2-Associated Cytokine Storm Syndromes.
Cabler SS; French AR; Orvedahl A
Trends Mol Med; 2020 Dec; 26(12):1078-1085. PubMed ID: 33051104
[TBL] [Abstract][Full Text] [Related]
29. Effect of the Phytochemical Agents against the SARS-CoV and Some of them Selected for Application to COVID-19: A Mini-Review.
Idrees M; Khan S; Memon NH; Zhang Z
Curr Pharm Biotechnol; 2021; 22(4):444-450. PubMed ID: 32619167
[TBL] [Abstract][Full Text] [Related]
30. Can molecular mimicry explain the cytokine storm of SARS-CoV-2?: An in silico approach.
Obando-Pereda G
J Med Virol; 2021 Sep; 93(9):5350-5357. PubMed ID: 33913542
[TBL] [Abstract][Full Text] [Related]
31. Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19.
Sell SL; Prough DS; Weisz HA; Widen SG; Hellmich HL
PLoS One; 2021; 16(9):e0257965. PubMed ID: 34587192
[TBL] [Abstract][Full Text] [Related]
32. Pathogenesis guided therapeutic management of COVID-19: an immunological perspective.
Kumar A; Prasoon P; Sekhawat PS; Pareek V; Faiq MA; Kumari C; Narayan RK; Kulandhasamy M; Kant K
Int Rev Immunol; 2021; 40(1-2):54-71. PubMed ID: 33111578
[TBL] [Abstract][Full Text] [Related]
33. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
Front Immunol; 2020; 11():1949. PubMed ID: 32849654
[TBL] [Abstract][Full Text] [Related]
34. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.
Olajide OA; Iwuanyanwu VU; Lepiarz-Raba I; Al-Hindawi AA
Inflammation; 2021 Oct; 44(5):1865-1877. PubMed ID: 33860869
[TBL] [Abstract][Full Text] [Related]
35. Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19).
Andrew M; Jayaraman G
Carbohydr Res; 2021 Jul; 505():108326. PubMed ID: 34015720
[TBL] [Abstract][Full Text] [Related]
36. A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.
Ahmed F
Front Immunol; 2020; 11():590459. PubMed ID: 33362771
[TBL] [Abstract][Full Text] [Related]
37. The roles of Eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: inflammasome and JaK inhibitors as potential promising therapies.
Zalpoor H; Akbari A; Samei A; Forghaniesfidvajani R; Kamali M; Afzalnia A; Manshouri S; Heidari F; Pornour M; Khoshmirsafa M; Aazami H; Seif F
Cell Mol Biol Lett; 2022 Feb; 27(1):10. PubMed ID: 35109786
[TBL] [Abstract][Full Text] [Related]
38. Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice.
Ghasemzadeh M; Ghasemzadeh A; Hosseini E
Hum Immunol; 2022 Jan; 83(1):86-98. PubMed ID: 34583856
[TBL] [Abstract][Full Text] [Related]
39. Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19.
Kumar R; Rathi H; Haq A; Wimalawansa SJ; Sharma A
Virus Res; 2021 Jan; 292():198235. PubMed ID: 33232783
[TBL] [Abstract][Full Text] [Related]
40. Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.
Zarei M; Sahebi Vaighan N; Ziai SA
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):633-643. PubMed ID: 34647511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]